Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 262 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Demyelinating Autoimmune Diseases, Central Nervous System (CNS) Clear all
Completed Not applicable Interventional

Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study

NCT05301335
View directory record Official record
Conditions
Neurogenic Bladder, Spinal Cord Injuries (Complete and Incomplete), Stroke, Multiple Sclerosis
Interventions
SCONE
Device
Lead sponsor
SpineX Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Downey, California • San Diego, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

NCT00030966
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2009 · Synced Oct 23, 2026, 10:51 AM EDT
Active, not recruiting Not applicable Interventional

An Online Nurse-Led Purpose-Focused Group Program for Adult Women With Multiple Sclerosis: Effects on Meaning and Quality of Life

NCT07555015
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Nurse-Led Purpose-Building Intervention
Behavioral
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Denton, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 10:51 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

NCT06999434
View directory record Official record
Conditions
Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis), SCI - Spinal Cord Injury, Spinal Radiculopathy
Interventions
[ 18F]3F4AP, [18F]MK6240, [11C]PIB
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 10:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Non-invasive BCI-controlled Assistive Devices

NCT05183152
View directory record Official record
Conditions
Motor Disorders, Healthy, Spinal Cord Injuries, Muscular Diseases, Motor Neuron Disease, Stroke, Traumatic Brain Injury, Movement Disorders, Multiple Sclerosis
Interventions
NMES Feedback, Visual Feedback, TESS
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Not applicable Interventional Results available

Impact of Custom Assistive and Adaptive Technology in Rehabilitation

NCT03567239
View directory record Official record
Conditions
Disability Physical, Brain Injuries, Stroke, Spinal Cord Injuries, Multiple Sclerosis, Paralysis
Interventions
Using adaptive device.
Device
Lead sponsor
Madonna Rehabilitation Hospital
Other
Eligibility
1 Year to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 2 Interventional

Rolipram to Treat Multiple Sclerosis

NCT00011375
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rolipram
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

NCT01201356
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Fingolimod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
34
States / cities
Cullman, Alabama • Oceanside, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

NCT05116540
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
HB-adMSCs, Placebo
Biological · Drug
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

NCT02166346
View directory record Official record
Conditions
Transverse Myelitis, Neuromyelitis Optica, Idiopathic Transverse Myelitis, Myelitis NOS
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 23, 2026, 10:51 AM EDT
Terminated Phase 1 Interventional

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

NCT03656627
View directory record Official record
Conditions
Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions
Nivolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals

NCT06117020
View directory record Official record
Conditions
Muscle Spasticity, Hypertonia, Muscle, Cerebral Palsy, Multiple Sclerosis, Stroke, Hereditary Spastic Paraplegia, Dystonia, Spinal Cord Injuries
Interventions
MTR-601
Drug
Lead sponsor
Motric Bio
Industry
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 23, 2026, 10:51 AM EDT
Recruiting Phase 1 Interventional

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

NCT07224373
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
AZD0120 - Regimen 1, AZD0120 - Regimen 2
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 10:51 AM EDT
Completed No phase listed Observational

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

NCT00464074
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
30
States / cities
Phoenix, Arizona • Fresno, California • Atlanta, Georgia + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 23, 2026, 10:51 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

NCT05201638
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
IMU-838 tablets, Placebo matching IMU-838 tablets
Drug
Lead sponsor
Immunic AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
2
States / cities
Altamonte Springs, Florida • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

NCT04201262
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Ravulizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 23, 2026, 10:51 AM EDT
Suspended Phase 1 Interventional

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

NCT06677710
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
Interventions
IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna
Drug
Lead sponsor
Indapta Therapeutics, INC.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 23, 2026, 10:51 AM EDT
Not listed Not applicable Interventional

Mobility Rehab, a Therapist-assisted System for Gait Rehabilitation

NCT03869879
View directory record Official record
Conditions
Parkinson Disease, Stroke, Multiple Sclerosis, Gait Disorders, Neurologic, Gait Disorder, Sensorimotor, Gait, Unsteady, Gait Ataxia, Gait, Stumbling, Gait, Shuffling
Interventions
Feedback-assisted physical therapy, Traditional physical therapy
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
60 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salem, Oregon
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 23, 2026, 10:51 AM EDT
Not listed Not applicable Interventional

Autologous Stem/Stromal Cells in Neurological Disorders and Disease

NCT03297177
View directory record Official record
Conditions
Dementia, Parkinson, Altered Behavior in Alzheimer Disease, Demyelinating Autoimmune Diseases, CNS, Demyelinating Sensorimotor Neuropathy, Corticobasal Degeneration
Interventions
Microcannula Harvest Adipose, Centricyte 1000, Sterile Normal Saline Infusion
Procedure · Device
Lead sponsor
Regeneris Medical
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
North Attleboro, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 23, 2026, 10:51 AM EDT
Completed No phase listed Observational

A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment

NCT00702065
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Phoenix, Arizona • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 23, 2026, 10:51 AM EDT
Active, not recruiting Not applicable Interventional

Remote Therapeutic Monitoring Exercise Tracking

NCT06306768
View directory record Official record
Conditions
Parkinson Disease, Multiple Sclerosis
Interventions
Activity Monitoring
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 1 Interventional

Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions

NCT00970333
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Multiple Sclerosis
Interventions
[18F]-FEPPA
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Oct 23, 2026, 10:51 AM EDT
Completed No phase listed Observational

Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients

NCT02099370
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis

NCT00097188
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • Modesto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 23, 2026, 10:51 AM EDT